Evidence map›Paper›PMID 38927459›Full record

ArticleBiomedicines2024

Synthesis and Characterization of Click Chemical Probes for Single-Cell Resolution Detection of Epichaperomes in Neurodegenerative Disorders.

Sadik Bay, Chander S Digwal, Ananda M Rodilla Martín, Sahil Sharma, Aleksandra Stanisavljevic, Anna Rodina, Anoosha Attaran, Tanaya Roychowdhury, Kamya Parikh, Eugene Toth and 9 more

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sadik BayChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-8089-1330
Chander S DigwalChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-8784-1096
Ananda M Rodilla MartínChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sahil SharmaChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-7281-9224
Aleksandra StanisavljevicCenter for Dementia Research, Nathan Kline Institute, Orangeburg, NY 10962, USA.
Anna RodinaChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Anoosha AttaranDepartment of Physiology and Pharmacology, Schulich School of Medicine, Robarts Research Institute, The University of Western Ontario, London, ON N6A 3K7, Canada.
Tanaya RoychowdhuryChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kamya ParikhChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0009-0005-1085-3861
Eugene TothChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0009-0005-1972-5962
Palak PanchalChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eric RosiekMolecular Cytology Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chiranjeevi PasalaChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-5612-6241
Ottavio ArancioTaub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, NY 10032, USA.
Paul E FraserTanz Centre for Research in Neurodegenerative Diseases and Department of Medical Biophysics, University of Toronto, Toronto, ON M5R 0A3, Canada.ORCID 0000-0003-1227-4239
Melissa J AlldredCenter for Dementia Research, Nathan Kline Institute, Orangeburg, NY 10962, USA.
Marco A M PradoDepartment of Physiology and Pharmacology, Schulich School of Medicine, Robarts Research Institute, The University of Western Ontario, London, ON N6A 3K7, Canada.
Stephen D GinsbergCenter for Dementia Research, Nathan Kline Institute, Orangeburg, NY 10962, USA.ORCID 0000-0002-1797-4288
Gabriela ChiosisChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Michael Jason de la Cruz · 1985 to 2026
$347.4M
TAU, AB, SYNUCLEIN AND NITRATIVE/OXIDATIVE DAMAGE IN MCIP01AG014449 · NIA · UNIVERSITY OF PITTSBURGH · PI MUFSON, ELLIOTT JAY · 1997 to 2024
$39.7M
Project 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI LI, ZIHAI · 2015 to 2019
$6.7M
Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrumR01AG074004 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, GINSBERG, STEPHEN D · 2021 to 2025
$6.0M
Chaperome networks in Alzheimer's diseaseR01AG067598 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI ARANCIO, OTTAVIO, CHIOSIS, GABRIELA · 2021 to 2025
$5.9M
Selective interactome vulnerability across the Alzheimer’s disease spectrumR01AG072599 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI GABRIELA CHIOSIS, STEPHEN D GINSBERG · 2023 to 2026
$5.4M
[18F]-PU-AD epichaperome PET imaging probeRF1AG071805 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2022 to 2025
$4.8M
Neuropathology and inflammation in a nonhuman primate model of insulin resistance/metabolic syndromeR01AG085572 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI STEPHEN D GINSBERG, PETER J HAVEL · 2024 to 2026
$3.8M
Small molecule Hsp90 inhibitors in AD treatmentU01AG032969 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2010 to 2014
$3.5M
Biomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9M
Septhohippocamal connectome dysfunction in Down syndrome associated with Alzheimer’s disease pathophysiologyRF1AG077103 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GINSBERG, STEPHEN D, STUTZMANN, GRACE E. · 2023 to 2023
$2.5M
A chemical chaperomics platform for ADR56AG061869 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2018 to 2019
$1.8M
NCI NIH HHS P01 CA186866NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA172546NIA NIH HHS P01 AG014449NIA NIH HHS R01 AG067598NIA NIH HHS R01 AG072599NIA NIH HHS R01 AG074004NIA NIH HHS R01 AG085572NIA NIH HHS R56 AG061869NIA NIH HHS R56 AG072599NIA NIH HHS RF1 AG071805NIA NIH HHS RF1 AG077103NIA NIH HHS U01 AG032969
6 · The paper itself

Abstract

Neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD), represent debilitating conditions with complex, poorly understood pathologies. Epichaperomes, pathologic protein assemblies nucleated on key chaperones, have emerged as critical players in the molecular dysfunction underlying these disorders. In this study, we introduce the synthesis and characterization of clickable epichaperome probes, PU-TCO, positive control, and PU-NTCO, negative control. Through comprehensive in vitro assays and cell-based investigations, we establish the specificity of the PU-TCO probe for epichaperomes. Furthermore, we demonstrate the efficacy of PU-TCO in detecting epichaperomes in brain tissue with a cellular resolution, underscoring its potential as a valuable tool for dissecting single-cell responses in neurodegenerative diseases. This clickable probe is therefore poised to address a critical need in the field, offering unprecedented precision and versatility in studying epichaperomes and opening avenues for novel insights into their role in disease pathology.

Indexed as

click probesdrug discoveryepichaperomesfluorescence imagingimaging probeneurodegenerative diseasetherapeutic strategy

Identifiers

PMID38927459
PMCPMC11201208

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.